IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting
| INAB Stock | USD 0.32 0.01 3.23% |
About 54% of In8bio's investors are presently thinking to get in. The analysis of the overall investor sentiment regarding In8bio Inc suggests that some traders are interested. The current market sentiment, together with In8bio's historical and current headlines, can help investors time the market. In addition, many technical investors use In8bio Inc stock news signals to limit their universe of possible portfolio assets.
In8bio |
INB-100 continues to demonstrate durable complete remissions with no relapses observed in any acute myeloid leukemia patients including those with high-risk disease after a median follow-up of 19.7 months. Data highlights INB-100s long-term impact, exhibiting durable in vivo expansion and persistence of allogeneic gamma-delta T cells 365 days following a single administration of INB-100, demonstrating the first-ever durable persistence and expansion of an allogeneic cellular therapy.
Read at finance.yahoo.com
 |
In8bio Fundamental Analysis
We analyze In8bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of In8bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of In8bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
In8bio is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
In8bio Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with In8bio stock to make a market-neutral strategy. Peer analysis of In8bio could also be used in its relative valuation, which is a method of valuing In8bio by comparing valuation metrics with similar companies.
Peers
In8bio Related Equities
| CNSP | Cns Pharmaceuticals | 9.09 | ||||
| CUE | Cue Biopharma | 4.14 | ||||
| PYPD | PolyPid | 3.68 | ||||
| INMB | INmune Bio | 3.58 | ||||
| RVPH | Reviva Pharmaceuticals | 0.53 | ||||
| ANNX | Annexon | 0.21 | ||||
| ZURA | Zura Bio | 0.46 | ||||
| LTRN | Lantern Pharma | 0.77 | ||||
| ALLR | Allarity Therapeutics | 2.80 | ||||
| WINT | Windtree Therapeutics | 3.70 | ||||
| ANIX | Anixa Biosciences | 4.66 | ||||
| PALI | Palisade Bio | 4.98 | ||||
| GANX | Gain Therapeutics | 5.74 | ||||
| WVE | Wave Life | 7.68 |
Complementary Tools for In8bio Stock analysis
When running In8bio's price analysis, check to measure In8bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy In8bio is operating at the current time. Most of In8bio's value examination focuses on studying past and present price action to predict the probability of In8bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move In8bio's price. Additionally, you may evaluate how the addition of In8bio to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |